TY - JOUR
T1 - Assay of Rab25 function in ovarian and breast cancers
AU - Cheng, Kwai Wa
AU - Lu, Yiling
AU - Mills, Gordon B.
N1 - Funding Information:
K.W.C. was supported by the Odyssey Program of the Houston Endowment Scientific Achievement award from the MD Anderson Cancer Center. This work is supported by National Institutes of Health SPORE (P50‐CA83639) and PPG‐PO1 CA64602 to G.B.M.
PY - 2005
Y1 - 2005
N2 - There is a multitude of critical steps during the pathogenesis of cancer that allow cells to acquire the ability to escape from normal controls on cell growth, to avoid programmed cell death, and to become malignant. Here, we describe a molecular approach that can be broadly applied to identify drivers of genomic aberrations in cancer development. In the process, areas of genomic aberrations and genes that are dysregulated by genomic amplification are identified by array comparative genomic hybridization (CGH) and transcription profiling, respectively, with major emphasis on coordinating amplification at the CGH and RNA level and on correlation with patient's outcomes. Once candidate genes are identified, we perform functional genomics by manipulating levels in normal and tumor cells using RNAi or transfection, and assessing a battery of cellular functions including proliferation, anti-apoptosis, loss of contact inhibition, changes in cell signaling or transcriptional profiles, anchorage-independent growth, and in vivo tumor growth. We have successfully used this approach to identify the RAB25 gene that has been implicated in the progression and aggressiveness of ovarian and breast cancers.
AB - There is a multitude of critical steps during the pathogenesis of cancer that allow cells to acquire the ability to escape from normal controls on cell growth, to avoid programmed cell death, and to become malignant. Here, we describe a molecular approach that can be broadly applied to identify drivers of genomic aberrations in cancer development. In the process, areas of genomic aberrations and genes that are dysregulated by genomic amplification are identified by array comparative genomic hybridization (CGH) and transcription profiling, respectively, with major emphasis on coordinating amplification at the CGH and RNA level and on correlation with patient's outcomes. Once candidate genes are identified, we perform functional genomics by manipulating levels in normal and tumor cells using RNAi or transfection, and assessing a battery of cellular functions including proliferation, anti-apoptosis, loss of contact inhibition, changes in cell signaling or transcriptional profiles, anchorage-independent growth, and in vivo tumor growth. We have successfully used this approach to identify the RAB25 gene that has been implicated in the progression and aggressiveness of ovarian and breast cancers.
UR - http://www.scopus.com/inward/record.url?scp=32444446461&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=32444446461&partnerID=8YFLogxK
U2 - 10.1016/S0076-6879(05)03017-X
DO - 10.1016/S0076-6879(05)03017-X
M3 - Review article
C2 - 16473588
AN - SCOPUS:32444446461
SN - 0076-6879
VL - 403
SP - 202
EP - 215
JO - Methods in enzymology
JF - Methods in enzymology
M1 - 17
ER -